S. L. Cohn, A. D. Pearson, W. B. London, T. Monclair, P. F. Ambros et al., The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report, Journal of Clinical Oncology, vol.27, issue.2, pp.289-297, 2009.
DOI : 10.1200/JCO.2008.16.6785

I. Janoueix-lerosey, G. Schleiermacher, E. Michels, V. Mosseri, A. Ribeiro et al., Overall Genomic Pattern Is a Predictor of Outcome in Neuroblastoma, Journal of Clinical Oncology, vol.27, issue.7, pp.1026-1033, 2009.
DOI : 10.1200/JCO.2008.16.0630

URL : https://hal.archives-ouvertes.fr/inserm-00369944

H. Caren, F. Abel, P. Kogner, and T. Martinsson, gene in advanced sporadic neuroblastoma tumours, Biochemical Journal, vol.416, issue.2, pp.153-159, 2008.
DOI : 10.1042/BJ20081834

URL : https://hal.archives-ouvertes.fr/hal-00479097

Y. Chen, J. Takita, Y. L. Choi, M. Kato, M. Ohira et al., Oncogenic mutations of ALK kinase in neuroblastoma, Nature, vol.20, issue.7215, pp.971-974, 2008.
DOI : 10.1038/nature07399

R. E. George, T. Sanda, M. Hanna, S. Frohling, W. Luther et al., Activating mutations in ALK provide a therapeutic target in neuroblastoma, Nature, vol.25, issue.7215, pp.975-978, 2008.
DOI : 10.1038/nature07397

D. Janoueix-lerosey, D. Lequin, L. Brugieres, A. Ribeiro, V. Combaret et al., Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma, Nature, vol.40, issue.7215, pp.967-970, 2008.
DOI : 10.1038/nature07398

Y. P. Mosse, M. Laudenslager, L. Longo, K. A. Cole, A. Wood et al., Identification of ALK as a major familial neuroblastoma predisposition gene, Nature, vol.25, issue.7215, pp.930-935, 2008.
DOI : 10.1038/nature07261

I. Janoueix-lerosey, G. Schleiermacher, and O. Delattre, Molecular pathogenesis of peripheral neuroblastic tumors, Oncogene, vol.23, issue.11, pp.1566-1579, 2010.
DOI : 10.1158/0008-5472.CAN-06-4443

G. Barone, J. Anderson, A. D. Pearson, K. Petrie, and L. Chesler, New Strategies in Neuroblastoma: Therapeutic Targeting of MYCN and ALK, Clinical Cancer Research, vol.19, issue.21, pp.5814-5821, 2013.
DOI : 10.1158/1078-0432.CCR-13-0680

S. C. Bresler, A. C. Wood, E. A. Haglund, J. Courtright, L. T. Belcastro et al., Differential Inhibitor Sensitivity of Anaplastic Lymphoma Kinase Variants Found in Neuroblastoma, Science Translational Medicine, vol.3, issue.108, pp.108-114, 2011.
DOI : 10.1126/scitranslmed.3002950

E. L. Carpenter and Y. P. Mosse, Targeting ALK in neuroblastoma???preclinical and clinical advancements, Nature Reviews Clinical Oncology, vol.23, issue.7, pp.391-399, 2012.
DOI : 10.1038/nrclinonc.2012.72

Y. P. Mosse, M. S. Lim, S. D. Voss, K. Wilner, K. Ruffner et al., Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study, The Lancet Oncology, vol.14, issue.6, pp.472-480, 2013.
DOI : 10.1016/S1470-2045(13)70095-0

B. J. Hindson, K. D. Ness, D. A. Masquelier, P. Belgrader, N. J. Heredia et al., High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy Number, Analytical Chemistry, vol.83, issue.22, pp.8604-8610, 2011.
DOI : 10.1021/ac202028g

J. A. Beaver, D. Jelovac, S. Balukrishna, R. L. Cochran, S. Croessmann et al., Detection of Cancer DNA in Plasma of Patients with Early-Stage Breast Cancer, Clinical Cancer Research, vol.20, issue.10, pp.2643-2650, 2014.
DOI : 10.1158/1078-0432.CCR-13-2933

V. Combaret, C. Audoynaud, I. Iacono, M. C. Favrot, M. Schell et al., Circulating MYCN DNA as a tumor-specific marker in neuroblastoma patients, Cancer Res, vol.62, pp.3646-3648, 2002.

V. Combaret, C. Bergeron, R. Noguera, I. Iacono, and A. Puisieux, -Amplification in Neuroblastoma, Journal of Clinical Oncology, vol.23, issue.34, pp.8919-8920, 2005.
DOI : 10.1200/JCO.2005.04.0170

URL : https://hal.archives-ouvertes.fr/hal-01305344

V. Combaret, M. D. Hogarty, W. B. London, P. Mcgrady, I. Iacono et al., amplification, Pediatric Blood & Cancer, vol.341, issue.3, pp.329-331, 2009.
DOI : 10.1002/pbc.22009

V. Combaret, S. Brejon, I. Iacono, G. Schleiermacher, G. Pierron et al., Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA, Pediatric Blood & Cancer, vol.22, issue.5, pp.757-761, 2011.
DOI : 10.1002/pbc.22816

URL : https://hal.archives-ouvertes.fr/hal-00788900

T. Gotoh, H. Hosoi, T. Iehara, Y. Kuwahara, S. Osone et al., Amplification in Neuroblastoma Using Serum DNA and Real-Time Quantitative Polymerase Chain Reaction, Journal of Clinical Oncology, vol.23, issue.22, pp.5205-5210, 2005.
DOI : 10.1200/JCO.2005.02.014

V. Moroz, D. Machin, A. Faldum, B. Hero, T. Iehara et al., Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project, European Journal of Cancer, vol.47, issue.4, pp.561-571, 2011.
DOI : 10.1016/j.ejca.2010.10.022

G. M. Brodeur, J. Pritchard, F. Berthold, N. L. Carlsen, V. Castel et al., Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment., Journal of Clinical Oncology, vol.11, issue.8, pp.1466-1477, 1993.
DOI : 10.1200/JCO.1993.11.8.1466

M. Ramirez, ROC (receiver operating characteristics) curve: principles and application in biology, Ann. Biol. Clin. (Paris), vol.63, pp.145-154, 2005.

G. Schleiermacher, N. Javanmardi, V. Bernard, Q. Leroy, J. Cappo et al., Mutations at Relapse of Neuroblastoma, Journal of Clinical Oncology, vol.32, issue.25, pp.2727-2734, 2014.
DOI : 10.1200/JCO.2013.54.0674

Y. Kuang, A. Rogers, B. Y. Yeap, L. Wang, M. Makrigiorgos et al., Noninvasive Detection of EGFR T790M in Gefitinib or Erlotinib Resistant Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.15, issue.8, pp.2630-2636, 2009.
DOI : 10.1158/1078-0432.CCR-08-2592

K. Page, D. S. Guttery, N. Zahra, L. Primrose, S. R. Elshaw et al., Influence of Plasma Processing on Recovery and Analysis of Circulating Nucleic Acids, PLoS ONE, vol.132, issue.10, p.77963, 2013.
DOI : 10.1371/journal.pone.0077963.s006

M. Sausen, R. J. Leary, S. Jones, J. Wu, C. P. Reynolds et al., Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma, Nature Genetics, vol.57, issue.1, pp.12-17, 2013.
DOI : 10.1038/ng.2493

F. A. Monzon, S. Ogino, M. E. Hammond, K. C. Halling, K. J. Bloom et al., The role of KRAS mutation testing in the management of patients with metastatic colorectal cancer, Arch. Pathol. Lab. Med, vol.133, pp.1600-1606, 2009.

K. C. Chan, P. Jiang, Y. W. Zheng, G. J. Liao, H. Sun et al., Cancer Genome Scanning in Plasma: Detection of Tumor-Associated Copy Number Aberrations, Single-Nucleotide Variants, and Tumoral Heterogeneity by Massively Parallel Sequencing, Clinical Chemistry, vol.59, issue.1, pp.211-224, 2013.
DOI : 10.1373/clinchem.2012.196014

N. F. Moore, A. M. Azarova, N. Bhatnagar, K. N. Ross, L. E. Drake et al., Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in <em>ALK</em>-mutated neuroblastoma, Oncotarget, vol.5, issue.18, pp.8737-8749, 2014.
DOI : 10.18632/oncotarget.2372